Background: Medulloblastoma is the most common malignant brain tumour of childhood. The identification of critical genes involved in its pathogenesis will be central to advances in our understanding of its molecular basis, and the development of improved therapeutic approaches.
Introduction
Medulloblastoma is an invasive embryonal tumour of the cerebellum, and the most common malignant brain tumour in children. Although overall five-year survival rates of 60-70% are now achieved, a significant proportion of cases will die from their disease, and the intensive chemotherapeutic and radiotherapy regimes employed in treatment are associated with long-term neuroendocrine and cognitive dysfunction in surviving patients. Advances in our understanding of the biology of medulloblastoma will be essential to future improvements in therapeutic outcome, through strategies including the identification of specific targets for the development of novel therapies, and biomarkers for improved treatment stratification [1, 2] .
The identification of specific genetic defects has been central to advances in our understanding of the molecular basis of medulloblastoma. A series of non-randomly mutated genes have been identified, which have, in turn, led to the characterisation of critical roles for their associated biological pathways in sub-sets of cases; the Wnt/Wingless (WNT) signalling pathway is activated by mechanisms including CTNNB1 mutation in 10-15% cases, and the Sonic hedgehog (SHH) pathway in activated in a further 20-25%, predominantly by mutations in PTCH1 [1] [2] [3] [4] [5] . The most prevalent genomic amplifications reported to date affect the MYC and MYCN oncogenes (each in 5-15% of cases), and homozygous deletions of established tumour suppressor genes, including CDKN2A and P14ARF, have been described [6] [7] [8] . Importantly, genetic defects have therapeutic relevance; markers of favourable (WNT activation) and poor (MYC/MYCN amplification) prognosis have been identified and validated in clinical trials cohorts [6, 9, 10] , and small molecule inhibitors of the SHH pathway are under pre-clinical development [11] .
Despite these advances, the critical genes involved in medulloblastoma development are otherwise poorly understood, and specific genetic defects remain to be identified in the majority of cases. We therefore undertook a comprehensive SNP-array based analysis of copy number defects in medulloblastoma cell lines, to identify regions of genomic amplification and homozygous deletion, which may harbour critical medulloblastoma genes. We report the validation, mapping and further characterisation of recurrent novel genetic regions identified, in medulloblastoma cell lines and primary tumours, and use these data to identify putative target gene(s) which may contribute to medulloblastoma development.
Methods
Primary tumours, tissues and cell lines 37 primary medulloblastoma samples were analysed in this study. The cohort included 22 male and 14 female patients (1 unknown), aged 1.3 to 40 years at diagnosis (1 infant (,3 years), 31 children ($3 to 15 years) and 4 adults ($16 years)). Histopathological review identified 27 cases of classic medulloblastoma, 4 cases of nodular/desmoplastic medulloblastoma, 5 cases of largecell/anaplastic medulloblastoma and one case of undefined histological variant [12] . Four non-neoplastic cerebellar samples (aged 10 months to 67 years) were also investigated. All aspects of this study have been approved by the Newcastle & North Tyneside NHS Trust research ethics committee (approval 07/Q0905/71). Written Informed consent for tumour collection, storage and research was obtained for all primary medulloblastomas, from participants or their parents/legal guardians. Under the terms of the research ethics committee approval for this study, and the UK Human Tissue Act (2006), consent was not required for the normal cerebellar material, as it was collected prior to 2006. Eight medulloblastoma cell lines were investigated (DAOY, D384MED, D425MED, D458MED, D341MED, D283MED, MHH-MED-1, MHH-MED-8A), cultured and maintained as previously described ). Genomic DNA from samples was extracted using the Nucleon hard tissue kit (Nucleon Biosciences) or by the TRIzol method (Invitrogen), according to the manufacturer's instructions. RNA was extracted from samples using the TRIzol method (Invitrogen), and treated with DNAse I (Ambion) to eliminate contaminating DNA.
SNP-array analysis
Genomic DNA samples from the eight medulloblastoma cell lines were analysed using the GeneChipH Mapping 10K 2.0 Array (Affymetrix), and raw data processed using Microsoft Excel spreadsheets, as previously described [13] . The raw SNP array data is available freely from the Cancer Genome Project, subject to completion of a data access agreement (http://www.sanger.ac. uk/genetics/CGP/Archive/). Data were used to identify markers displaying evidence of genomic amplification or homozygous deletion, which were defined as follows: intensity ratio (or haploid copy number (HCN)).2.5, amplification or high-level gain; HCN,0.1, homozygous deletion. Physical positions of probes and genes were identified according to the SNP consortium (TSC) database (http://www.hapmap.org/) and the NCBI database build 36.2 (http://www.ncbi.nih.nlm.gov). The estimated maximal regions of continuous defects affecting multiple probes were identified by the physical positions of the nearest flanking unaffected probe at each end.
Quantitative real-time PCR
Analysis of hsa-miR-30b and hsa-miR-30d expression, measured relative to a U6 non-coding RNA control, was performed using proprietary TaqManH MicroRNA real-time PCR Assay primer sets and reagents (Applied Biosystems), based on absolute quantification, following the manufacturer's instructions. All other analyses were performed using real-time PCR, based on the SYBR Green JumpStart Taq ReadyMix system (Sigma). Absolute quantification was applied to copy number analysis, whereas relative quantification was applied to expression analysis. B2M, RPLP0 and TBP were used as reference genes for copy number analysis, and 28s rRNA was used as the reference gene for expression analysis. Details of primers used for these PCRs are shown in Supplementary Tables S1, S2 & S3. All real-time PCR assays were undertaken on an ABI PRISM 9700HT (Applied Biosystems) real-time PCR system.
Fluorescence in situ hybridisation
Interphase fluorescence in situ hybridization (iFISH) was performed in medulloblastoma cell lines using BAC clones RP11-383N10 (representing sequences at 8q24.23; obtained from The Wellcome Trust Sanger Institute, Cambridge), dJ968N11 (representing MYC [6] ) and pZ8.4 (representing the centromere of chromosome 8 [6] ), as previously described [6, 14] .
Results
SNP-array based copy number analysis of medulloblastoma cell lines: Identification of a novel region of recurrent genomic amplification at 8q23.22-q23.24 specific to medulloblastoma Raw 10K SNP-array data generated from 8 medulloblastoma cell lines were analysed and converted to graphical plots, as previously described [13] . Wider chromosomal defects identified were consistent with our previous genome-wide studies of these cell lines using loss of heterozygosity and conventional comparative genomic hybridisation methods (data not shown [14] ). However, high-resolution SNP array identified a number of focal defects for further investigation, and we elected to focus our analysis on these regions of putative genomic amplification or homozygous deletion, which may contain critical oncogenes or tumour suppressor genes in medulloblastoma development. Defects affecting at least three consecutive markers were classified as significant and, using these criteria, evidence of both genomic amplifications and homozygous deletions were observed ( Figure 1A ), which are summarised in Figure 1B . The majority of these regions either harboured known critical cancer-related genes or affected previously described features of medulloblastoma; amplification of MYC at 8q24.21, a well established feature of medulloblastoma [1, 2, 6] , was the only recurrent event detected which affected an established cancer-related gene, seen in 4/8 cell lines analysed. Homozygous deletions of (i) the 9p21.1-p21.3 region encompassing CDKN2A, CDKN2B and ARF and (ii) the 6q23.1 region, each observed in a single cell line, have previously been reported in medulloblastoma and other cancer types [7, 8, 15, 16] . A novel high level gain/amplification at 17q21.31, in conjunction with evidence of isochromosome (17q) (i(17q)) (i.e. gain of the q-arm and loss of the p-arm of chromosome 17), the most common cytogenetic feature of medulloblastoma [1, 2] , was found in the D425MED line. Notably, a single novel region of recurrent genomic high level gain/amplification was observed, at 8q23.22-q23.24, in two independent medulloblastoma cell lines (D341MED and D384MED). This novel feature at 8q24.22-q24.23 is of particular interest since (i) it was observed in multiple cell lines, and (ii) no evidence of amplification at this region was found in the analysis of over 800 other cancer cell lines derived from a wide range of different paediatric and adult cancer types using the GeneChipH Mapping 10K 2.0 Array (http://www.sanger.ac.uk/cgi-bin/ genetics/CGP/cghviewer/CghHome.cgi), suggesting this putative amplicon may contain gene(s) specifically related to medulloblastoma development. Additionally, we confirmed the independence of the D341MED and D384MED cell lines; each displayed a unique allelotype and harboured distinct genomic defects [14] . Therefore, we elected to further characterise this novel region in detail, and its role in medulloblastoma.
Verification, characterisation and physical mapping of the novel amplification at 8q24.22-q24.23 in medulloblastoma cell lines
The novel high-level gain/amplification observed at 8q24.22-q24.23 in D341MED and D384MED cell lines by SNP array was next investigated independently by iFISH. The BAC-clone RP11-383N10, which represents DNA sequences within this amplicon ( Figure 2E ), was used as a probe, and confirmed the presence of DNA amplification (.10 copies per control centromeric signal) in both cell lines (Figures 2A & B) , but not in the other cell lines examined (data not shown).
We noted that amplification of MYC at 8q24.21 and the novel region at 8q24.22-q24.23 was co-incident in both D341MED and D384MED. Although SNP-array data indicate that the regions of amplification are discrete ( Figure 1A) , the relationship between this novel amplification and MYC amplification at 8q24.21, was assessed by co-hybridization of RP11-383N10 and BAC probe dJ968N11, recognising MYC, in D384MED cells, to investigate whether their amplification was co-localised on a single amplicon. The combined result from over 100 cells indicated a mixed pattern of amplification in the cell population; MYC amplification alone was observed in 32% of cells, while the novel amplification alone was observed in 28% of the cell population. 22% of the cells showed amplification of both regions, but in two thirds of these cells, signals generated by the two BAC probes were not colocalised ( Figure 2C ).
The amplification status and physical gene content of the novel amplicon was additionally investigated using real-time PCR-based mapping. Analysis of the status of the coding genes within and surrounding the putative amplicon ( Figure 2E ) showed that ZFAT1, LOC286094 and KHDRBS3 were amplified in both cell lines D341MED and D384MED, but not in the non-amplified MHH-MED-8A line. The flanking genes, ST3GAL1 and FLJ45872, at the proximal and distal ends respectively of the amplified region, did not shown any evidence of amplification in any cell line ( Figure 2F ). LOC100130092, which encodes a predicted psudogene within the amplified region on the NCBI database (http://www.ncbi.nlm.nih.gov/), was not investigated. By SNP-array, physical mapping identified the amplicon extending from 134,810,164 bp (tsc0062042) to 137,820,222 bp (tsc0696464) in D341MED, and from 134,810,164 bp (tsc0062042) to 137,858,383 bp (tsc1392944) in D384MED, indicating a maximal common region of 3 Mb, extending from 134,810,164 bp to 137,820,222 bp.
Together, these data indicate that the novel amplification at 8q24.22-q24.23 is independent of MYC amplification and has consecutive gene content in both D341MED and D384MED, with the involved regions extending from ZFAT1 at its proximal end to KHDRBS3 at its distal end, and also encompasses LOC286094 and two genes encoding micro-RNAs (mi-RNAs), hsa-miR-30b and hsa-miR-30d.
Identification of putative target gene(s) of the novel amplification at 8q24.22-q24.23: investigation of relationships between gene amplification and transcript levels
To identify potential target genes of the novel amplification which may contribute to tumourigenesis, relationships between the transcript levels and copy numbers of genes contained in the novel amplicon were assessed in medulloblastoma cell lines using realtime PCR methods. High-level expression of hsa-miR-30b and hsa-miR-30d was closely correlated with their copy number status ( Figures 3A & B) , suggesting these may represent targets. No evidence of high-level expression of ZFAT1 or LOC286094, or correlation with gene copy number, was found in any cell line (data not shown), suggesting these do not represent candidate target genes. Data obtained for KHDRBS3 were less clear; highlevel expression was seen in three cell lines, however only one cell line of the three harboured the amplification, while no evidence of high-level expression was observed in the other amplified cell line ( Figure 3C ). Based on these findings, we next investigated the expression of the two mi-RNAs and KHDRBS3 in primary medulloblastomas and normal cerebellum, to further explore any roles in medulloblastoma development.
Transcript levels of candidate amplicon target genes and miRNAs in primary medulloblastomas and the normal cerebellum
Expression of mature hsa-miR-30b and hsa-miR-30d, as well as KHDRBS3, was analysed in cohorts of primary medulloblastoma samples, alongside four normal cerebellar samples, and data for medulloblastoma cell lines (n = 8) (Figure 4) . The highest mean level of expression observed in a normal cerebellar tissue sample was used as a threshold for the determination of overexpression in primary tumours and cell lines. Using these criteria, 54% (14/26), 12% (3/26) and 15% (3/20) of primary medulloblastomas showed evidence of overexpression of hsa-miR-30b, hsa-miR-30d, and KHDRBS3, respectively (Figure 4) . High-level expression of hsamiR-30b, comparable to levels observed in 8q24.22-q24.23 amplified cell lines, was observed in a sub-set of primary tumours. High-level expression of KHDRBS3, equivalent to levels observed in an 8q24.22-q24.23 amplified cell line, was also observed in a sub-set of primary tumours and other cell lines, but was not restricted to the 8q24.22-q24.23 amplified cell lines. Although expression levels of hsa-miR-30d in primary tumours were elevated relative to the normal cerebellum, they did not approach levels observed in 8q24.22-q24.23 amplified cell lines.
Analysis of genetic amplification at 8q24.22-q24.23 in primary medulloblastomas
The relative copy number of KHDRBS3, as a marker of the novel amplicon at 8q24.22-q24.23, was determined in all primary medulloblastoma samples in which the expression level was assessed (n = 37) by qPCR; no evidence of genomic amplification was observed (data not shown).
Discussion
This genome-wide SNP-array based screen has facilitated the characterisation of a series of focal regions of gene amplification and homozygous deletion in medulloblastoma, and the identification of putative target genes which may play critical roles in its development, and have therapeutic significance. In addition to the identification and further validation of established genomic events in medulloblastoma (e.g. MYC amplification, CDKN2A/B homozygous deletion [1,2,6-8]), defects have been identified which will, following further validation, aid investigations of the critical genetic targets of common medulloblastoma chromosomal aberrations. i(17q) is the most common chromosomal defect in medulloblastoma, affecting 30-40% of cases, and chromosome 6 loss is characteristic of the molecular disease sub-group defined by activation of the Wnt/Wingless cell signalling pathway [1] [2] [3] [4] [5] . The respective high level gain/amplification identified at 17q21.31, and the homozygous deletion at 6q23.1, will yield candidate target genes and facilitate the further mapping and investigation of these chromosomal aberrations.
The novel region of recurrent amplification identified at 8q24.33-q24.23 formed the focus of our further investigations. In addition to its recurrent nature, we have demonstrated its highcopy number amplification, independence of MYC amplification, and uniqueness to medulloblastoma amongst a panel of .800 cell lines derived from different tumour types, indicating this novel amplicon contains key gene(s) in medulloblastoma development, with the potential to inform critical insights to disease pathogenesis. The identification of the genetic target(s) of this novel amplicon, and their validation in studies of primary tumours, and in functional models, is therefore now paramount. Our detailed genetic mapping of its physical location and gene content, and investigation of their relationship to gene expression in medulloblastoma cell lines, identified KHSRBS3 and the genes encoding mi-RNA species, hsa-miR-30b and hsa-miR-30d, as putative oncogenic targets whose expression is closely correlated with amplification status.
In primary tumours, although we did not detect evidence of amplification of this target region in our cohort of primary medulloblastomas, consistent with data from a recent SNP-array screen of 212 primary medulloblastomas [8] , our investigations of the transcript levels of these target species further support roles in medulloblastoma. Based on these data, all three candidates, KHSRBS3, hsa-miR-30b and hsa-miR-30d, could be considered as potential targets of this novel amplification, as all showed elevated expression in a sub-set of primary medulloblastomas, measured relative to the normal cerebellum. hsa-miR-30b is arguably of most interest because, in addition to its high-level expression in cell lines which is closely correlated with amplification, it showed the greatest frequency of elevated expression in primary tumours (over 50% of cases), with expression levels detected in certain cases equivalent to those observed in amplified cell lines. Although such investigations were beyond the scope of the limited initial primary tumour cohort employed in the current study, the clinicopathological correlates of expression of all candidates in extensive, well characterised, and statistically powered clinical cohorts, is additionally likely to inform any potential roles in medulloblastoma.
Importantly, none of the three candidates can be fully excluded at this stage, and further investigations of their functional roles in medulloblastoma are required. The function(s) of KHDRBS3, hsamiR-30b and hsa-miR-30d, and in particular any roles they may play in tumourigenesis, have not been widely investigated, and this is the first study, to our knowledge, to investigate their status in medulloblastoma. KHDRBS3 (KH domain containing, RNA binding, signal transduction associated 3) belongs to a RNA binding protein family, and regulates the variant splicing of certain target genes [17] . Although one published study has demonstrated that expression of KHDRBS3 positively regulates telomerase activity in human colon cancer HCT-116 cells [18] , further details of KHDRBS3 function and association with cancers are not clear. Similarly, hsa-miR-30b and hsa-miR-30d have not been well characterised. Array-based studies have confirmed their expression in human tissues [19] [20] [21] , however on-line databases (e.g. miRBase; http://microrna.sanger.ac.uk/) predict .800 mRNA targets for each species, and their specific functions remain unclear. Nonetheless, the amplification and overexpression of hsamiR-30b and hsa-miR-30d in medulloblastoma further supports an emerging role for the dysregulation of mi-RNA species in medulloblastoma development [22] [23] [24] [25] [26] .
In summary, we have described a genome-wide screen of medulloblastoma cell lines to identify and characterise regions of gene amplification and homozygous deletion which may harbour critical genes in its development. Our findings implicate hsa-miR30b, hsa-miR-30d and KHDRBS3 as putative oncogenic target(s) of a novel recurrent medulloblastoma amplicon at 8q24.22-q24.23, which is independent of MYC amplification and unique to this disease. These data suggest specific and critical roles for these genes in medulloblastoma development for wider investigation, and further support the contribution of mi-RNA species to medulloblastoma pathogenesis. 
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